In addition to providing education, information and support to its 46 member-groups across 30 European countries, Myeloma Patients Europe (MPE) advocates for the best possible research and equal access to the most innovative treatment and care. With this aim, MPE has developed a series of Community Advisory Boards (CABs) focused on myeloma.

Based on the proven CML Advocates Network and ECAB model implemented by the HIV patient community and European AIDS Treatment Group (EATG), MPE held the first myeloma CAB from 11 to 13 May in Warsaw, Poland, to promote best-in class myeloma research as well as the harmonisation of good clinical practice, standard of care and access to best available myeloma therapies and diagnostic tools.

A range of topics were discussed in these successful meetings between sponsors and advocates. These included innovative therapies, access to myeloma drugs in Europe and patient involvement in medicines research and development.

The Myeloma-CAB Steering Committee will continue working on a series of CABs to create a trustworthy and strategic relationship among all stakeholders involved in the myeloma community.

Find more information about myeloma CABs here.